A. Persons with HIV should maintain on-hand at least a 1-year supply of antiretroviral drugs and other medications. B. People with HIV who have COVID-19 should be clinically managed the same as persons in the general population with COVID-19. C. Persons with HIV should switch their antiretroviral (ARV) regimens or add ARV drugs to their regimens for the purpose of preventing or treating SARS-CoV-2 infection. D. All persons with HIV are equally at risk of severe disease and of life-threatening COVID-19.

A. Weight increase among female patients and risk of diabetes was greatest in the TDF-based group. B. Weight increase among male patients and risk of diabetes was greatest in the TAF-based group. C. Weight increase among female patients and risk of diabetes was greatest in the TAF-based group. D. Weight increase among female patients and risk of diabetes was greatest with the EFV-containing regimen.

A. The proportion of participants with virologic response was superior in the Q4W group compared with the Q8W group. B. Virologic failure was not seen in either treatment arms. C. 98% of patients preferred Q4W to Q8W administration. D. Q8W was noninferior to Q4W in virologic response and virologic suppression.

A. DTG-containing regimens had superior virologic efficacy at delivery compared with EFV/FTC/TDF. B. EFV/FTC/TDF had lower frequency of adverse pregnancy outcomes compared with DTG+ TAF/FTC. C. EFV/FTC/TDF had superior virologic efficacy at delivery compared with DTG-containing regimens. D. TDF/FTC was better than TAF/FTC for pregnancy outcomes.

A. A patient who is virologically suppressed for at least 6 months and adherent to therapy B. A patient who is naïve to therapy, with a baseline HIV RNA of 400,000 copies/mL and is hepatitis B surface antigen–positive C. A person of childbearing potential using effective contraception D. A patient who is stable on TAF-based triple therapy